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Beta blockade with pindolol: Differential cardiac
and renal effects despite similar plasma kinetics
in normal and uremic man
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Department of Medicine and the Medizinische Poliklinik, University of Berne, Inseispital, Berne, Switzerland
Beta blockade with pindolol: Differential cardiac and renal ef-
fects despite similar plasma kinetics in normal and uremic man.
Cardiac and renal effects (measured as the reduction in exercise-
induced tachycardia and PRA, respectively) and circulating drug
concentrations after acute beta blockade with intravenous pindo-
lol were compared between seven normal volunteers and six pa-
tients with terminal renal failure. Kinetic parameters were simi-
lar in both groups (total body clearance, 450 mI/mm), indicating
enhanced extrarenal elimination in patients. For any given drug
concentration, however, the uremic patients responded to beta
blockade with a greater decrease in pulse rate than did normal
volunteers (P < 0.001). Moreover, in the same group, the de-
crease of PRA was more marked (from 13.3 to 5.7 vs. 3.3 to 1.9
ng/ml/hr) and lasted longer (8 hours and more vs. 2 hours).
Plasma aldosterone remained unchanged. These data reveal an
increased dependency of both heart rate and renin release on
beta adrenergic-mediated mechanisms in uremic man. They also
show that kinetic findings in normal subjects cannot always be
extrapolated to predict kinetic behavior in disease, and that simi-
lar kinetics do not imply similar effectiveness.
Blocage beta par le pindolol: Effets cardiaque et renal différents
malgré une cinétique plasmatique semblable, chez l'homme nor-
mal et urémique. Les effets cardiaque et renal (mesurés respec-
tivement par Ia reduction de tachycardie d'effort et PRA) et les
concentrations circulantes de Ia drogue après bloc beta aigu par
Ic pindolol intraveineux ont été compares entre sept volontaires
normaux et six malades atteints d'insuffisance rCnale terminale.
Les paramètres cinetiques sont semblables dans les deux
groupes (clearance totale, 450 mI/mm), ce qui indique une élimi-
nation extra-rénale augmentée chez les uremiques. Cependant,
pour une concentration donnëe de Ia drogue, les malades
rCpondent par une diminution plus grande de Ia fréquence cardi-
aque que chez les volontaires (P < 0,001). De plus, dans le
méme groupe, la diminution de PRA est plus importante (de
13,3 a 5,7 au lieu de 3,3 a 1,9 ng/ml/hr) et dure plus longtemps
(8 heures et plus au lieu de 2 heures). L'aldostërone plasma-
tique reste inchangee. Ces observations révèlent chez l'homme
uremique une dependance plus grande du rythme cardiaque
et de Ia liberation de refine vis-à-vis des mécanismes qui ont
pour médiateur le système beta-adrénergique. Elles montrent
aussi que les constatations cinétiques chez les sujets normaux ne
peuvent pas toujours étre extrapolCs a la prevision du comporte-
ment cinetique au cours des maladies et que des cinétiques
similaires n'impliquent pas la méme efficacité.
venous dose is about 3.5 hours, and 30 to 40% is
excreted unchanged in the urine [1]. Its overall
elimination rate has been reported to remain un-
changed with progressive impairment of renal func-
tion [2], suggesting increased extrarenal metabo-
lism. From mathematical evaluations, however,
others [3] have inferred that there is no increase in
nonrenal clearance of the drug with decreased
creatinine clearance. This seemed to be confirmed
by direct evaluation of hepatic clearance in hyper-
tensive patients treated with pindolol [4]. Thus, the
characteristics of pindolol handling in renal failure
are presently unclear. From a clinical viewpoint,
however, the effect of a drug is more important than
is its pharmacokinetics. We therefore applied acute
beta blockade with pindolol and compared the time
course of plasma concentrations and their relation-
ship with cardiac and renal effects between normal
subjects and patients with renal failure.
Methods
Subjects. Six patients and seven normal volun-
teers were studied. Age, sex, and body weight are
indicated in Table 1. The normal volunteers were
healthy medical students and were screened by
physical examination and routine laboratory tests
before the study. All patients had terminal renal
failure treated with hemodialysis. The diagnosis of
the underlying kidney disease was pyelonephritis or
intestitial nephritis in three patients, chronic gb-
merulonephritis in two, and polycystic kidney dis-
ease in one. Dialysis was performed two or three
The elimination half-life of pindobol, a potent
beta-blocking agent, after a single oral or intra-
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Table!. Sex, age, and weight of subjects
Mean body
9
Mean age
(and range)
years
weight
(and range)
kg
Patients 3 3 27
(22to33)
54
(44 to 62)
Normal subjects 7 0 23
(22 to 25)
73
(65 to90)
times (patient 13) weekly with arteriovenous fistulas
for blood access. Any drug therapy was kept stable
at least 2 weeks before the test. It included antacids
for all subjects, furosemide (80 to 250 mg/day, p.o.)
in three (patients 3, 4, 9), sulfodiazine in two (pa-
tients 3 and 9), and methyldopa (375 mg/day, patient
12), dihydralazine (150 mg/day, patient 3), chloro-
quine (patient 13), or allopurinol (patient 11). No
beta-blocking drugs were given. Blood pressure
was normal (<140/90) throughout the study. There
was no evidence of severe autonomic neuropathy
evidenced by orthostatic hypotension or dialysis-
hypotension hypersensitive to volume changes. The
patients were in fair condition and clinically stable.
No patients with obstructive lung disease, brady-
cardia below 60/mm, congestive heart failure, atrio-
ventricular block, liver or psychiatric diseases, or
inability to perform the required work at ergometry
were included.
Ergometry. The beta-blocking effect of pindolol
was measured as the reduction of exercise-induced
tachycardia. Subjects performed the exercise su-
pine on a vertically positioned bicycle. The day be-
fore the study, the workload producing a tachycar-
dia of 150 beats/mm after 3 mm was estimated
in a trial run. The heart rate was measured by a 3-
lead electrocardiograph (ECG) at a paper speed of
25 mm/sec, 15 seconds before the exercise and dur-
ing the last 15 seconds of the exercise. The 3-lead
EGG was also displayed on an oscilloscope.
Study design. Subjects reported to the hospital at
7.30 A.M. after a normal breakfast. Patients were
studied the day alter a dialysis treatment. After 10
mm of rest, the first exercise test was performed;
then, a blood sample was obtained from an antecu-
bital vein through a butterfly needle with heparin
lock. Subsequently, 3 mg of pindolol (Visken®, sup-
plied by Sandoz Ltd., Basle) was injected slowly
over 5 mm into a contralateral antecubital vein;
completion of the injection was taken as "0 time."
Exercise tests were repeated at 30, 60, 120 mm, 4,
6, 8, 10, 24, and 34 hours in patients and at 15, 30,
60, 90, 120 mm, 4, 6, 8, 10, 24, 34 hours in normal
volunteers. The exercise started 3 mm before the
time indicated, and blood samples for the determi-
nation of renin and aldosterone activity and pindol-
ol concentrations were taken at the end of each ex-
ercise. Lunch was taken after the 4-hour sample. Af-
ter the 10-hour sample, the subjects went home and
reported again to the clinic half an hour before the
24-hour and the 34-hour tests.
Biochemical methods. Plasma renin and aldoste-
rone were measured by radioimmunoassay [5, 6].
Pindolol concentration was determined by a flu on-
metric technique; because metabolites are eliminat-
ed during the extraction procedure, this method is
specific for unchanged pindolol [7].
Protein-binding analysis. Serum samples from
four patients on chronic hemodialysis treatment and
from two normal volunteers were used. The binding
was studied by a Dianorm equilibrium dialysis set,
with 1 ml of dialysis cells for the serum and 3 ml of
cells for the buffer. The cells were equipped with
Biachema membranes (Hp, 10,000). 14C-pindolol
was added to 1/15 M phosphate buffer (pH, 7.4),
made isotonic with sodium chloride. Dialysis was
carried out for 1 and 2 hours at 370 C. The percent
of bound pindolol was calculated as follows:
Percent bound =
j '4&PifldOlOl]serum — IL 1'C-pindolol]buffer
1'C-pindolol] serum
Analysis of the data. Nonlinear regression analy-
sis was done by using the log mean values of the
plasma concentrations (weighed by the number of
points contributing to the mean) according to the
following sum of two exponentials:
CP(t) = Aet + Be_13t (1)
where Cp(t) is the plasma concentration of pindolol,
A and B are the intercepts of the respective ex-
ponential terms, a is the "distribution rate con-
stant," and f3 is the "overall disposition rate con-
stant." Nonlinear regression was done with the
"NONLIN" program [8] on an IBM 370/158 com-
puter. Equation 1 represents a two-compartment
body model. The volume of distribution of the cen-
tral compartment (V1), the total volume of distribu-
tion (Vd), the total body clearance (C1TB), and the
nonrenal clearance (C1NR) were calculated according
to the following formulas [9]:
dose
= A + B
k12'Vd =
vi(i +
(2)
(3)
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CiTE = V1 x (elmination rate from the central
compartment) (4)
C1NR = C1TB — C1TB x fraction excreted unchanged
by the kidney) (5)
The accuracy of the model was checked by com-
paring CJTB calculated according to Equation 4, with
a clearance value calculated by dividing the area un-
der the concentration-time-curve into the dose.
The cardiac beta-blocking effect (E) is expressed
as the reduction of exercise-induced tachycardia af-
ter pindolol administration, calculated as follows:
/ET—ET0\E (% reduction) =
— (\ ET0 ) x 100
where ET0 is the pulse rate at the end of the 3 mm of
exercise before the administration of pindolol and
ET1 is the same at time t after pindolol. E was
plotted versus time to see whether there was a dif-
ference in the time course of the effect between nor-
mal subjects and patients with renal failure. E was
also plotted versus the logarithm of the plasma con-
centration [10] to see whether there were dif-
ferences in the concentration-effect relationship.
Results
Pharmacokinetics. The log mean values of pindo-
lol plasma concentrations, illustrated in Fig. 1, are
comparable in normal subjects and patients with
end-stage renal failure. Because body weight tend-
ed to be higher in normal than uremic subjects, the
higher plasma concentrations in the latter are due to
the slightly higher dose per kilogram of body weight
in patients with uremia. Blood levels related to
body weight, however, were similar in the two
groups, as indicated by the identical volumes of dis-
tribution per kilogram of body weight (Table 2). Al-
though blood samples were taken for more than 6
hours, the 8- and 10-hour pindolol concentrations
were not included in the analysis because they were
either immeasurable or below the sensitivity range
of the fluorimetric method used.
The mean of the logarithmic values was used be-
cause of the apparently nonnormal distribution of
the concentration values. From the summarized
pharmacokinetic parameters of the nonlinear re-
gression in Table 2, it appears that the total body
clearance values in both groups are equal. The total
volume of distribution per kilogram of body weight
is also in the same range. The total body clearance
per kilogram of body weight, however, is different
due to the slightly shorter beta half-life (0.05 <P <
0 1 3
Time, hours
Fig. 1. Mean (± SEM) plasma concentrations (ng/ml) after 3 mg
pindolol i.v. in normal volunteers and uremic patients, together
with the line of best fit.
0.1) calculated for the patients with renal failure.
The validity of the two-compartment body model to
describe the plasma kinetics of pindolol is stressed
by the fact that the clearance values, calculated by
the area method which gives a clearance independ-
ent of the number of compartments chosen, are
equal to the CITB values (445 and 443 mI/mm for nor-
mal subjects and patients with uremia, respective-
ly).
Protein-binding study. Protein binding at a total
serum concentration of 25 nglml was 41 (sEM)
1.4% for the two sera samples of normal subjects
and 40 3.4% for the samples from patients with
uremia. There was no increase in binding from the
first to the second hour. Binding to the membranes
was less than 1% of the total amount added.
Parameters Normal volunteers Patients
Fitted
A,ng . m1' 15.9 2.0 21.0 3.8
B,ng . m1' 21.2 0.87 29.2 1.5
a,min 0.0743 0.00641 0.081 0.01146
13,min1 0.00332 0.00035 0.00459 0.00054
Calculated
t'/2/3,min 209 151
V,, liters 80.7 59.62
Vd8,, liters 133 95
Vd8./kg body weight,
liters/kg 1.81 1.76
Total body clearance,
mi/mm 454 452
Percentage excreted
unchanged in the urine 46.7 0.5
Metabolic clearance,
mI/mm 242 450
102
0
0 ic 10
5.
E
to
2 4 5 6
Table 2. Table of pharmacokinetic parameters of pindolola
a Values represent the means Sn.
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Pharmacodynamics. Figure 2 shows that the
curves of the cardiac effect (expressed as the per-
cent reduction of exercise-induced tachycardia)
versus time in the two groups parallel each other
and the standard deviation encompasses the mean
values of the other group, indicating that there is no
impressive difference between the two groups in the
pharmacodynamic behavior over time.
A plot of the cardiac effects versus the log of
plasma concentrations (Fig. 3), however, shows
that patients with renal failure experience the same
effect at lower plasma concentrations than do nor-
mal volunteers. The "log dose-response curves"
are parallel (P > 0.5), but their intercepts are dif-
Time, hours
Fig. 2. Mean (± SD) percent reduction in exercise-induced tachy-
ardia over time after 3 mg of pindolol i.v. in normal volunteers
nd uremic patients.
—I
- I
2.5 5 10 20
Plasma pindolol, ng/mI
Fig. 3. Mean percent reduction of exercise-induced tachycardia
after 3 mg ofpindolol versus the logarithm of plasma concentra-
tions in normal man and uremic patients.
ferent (P < 0.001) [11]. Because Va/kg is equal in
both groups (Table 2), equal plasma concentrations
represent equal amounts of the drug in the body per
kilogram of body weight; this means that patients
need less drug per kilogram of body weight for the
same effect. To draw this figure, we used the calcu-
lated concentrations, according to the results of the
nonlinear regressions, to compare concentrations
and effects beyond the sixth hour.
Tables 3 and 4 show the values for plasma renin
and aldosterone. The normal volunteers had a mean
Table 3. PRA in normal subjects and patients after 3 mg of pindolol
PRA
nglml/hr
Ohr 0.5hr lhr 2hr 4hr 8hr 24hr 34hr
Normal subjects
#1 1.59 0.92 1.98 1.30 2.32 1.11 2.71 —
#2 6.59 — 4.17 2.99 6.96 4.68 7.46
#5 1.58 1.53 1.52 1.11 2.39 1.24 3.60 1.89
#6 3.49 2.27 2.13 1.86 6.53 3.28 5.32 5.34
#7 1.40 0.84 0.58 0.73 0.75 0.75 2.44 2.45
#8 2.32 1.15 0.96 0.94 1.51 1.61 4.44 2.71
#10 6.08 4.64 4.80 6.79 6.30 4.00 4.67 2.66
Mean 3.29 1.89 2.31 2.24 3.82 2.38 4.38 3.01
±SD ±2.20 ±1.44 ±1.59 ±2.14 ±2.66 ±1.57 ±1.71 ±1.34
±SEM ±0.83 ±0.59 ±0.60 ±0.81 ±1.00 ±0.59 ±0.65 ±0.60
Patients
#3 10.7 — 8.6 6.9 4.9 4.3 7.7 —
#4 18.3 — — — — 9.2 — —
#9 22.4 19.5 18.8 12.6 8.8 11.3 13.5 18.7
#11 15.9 16.0 17.2 13.0 9.9 6.7 10.8 13.9
#12 7.5 7.2 6.4 — 5.2 3.3 6.2 5.9
#13 5.3 5.3 4.7 3.3 3.1 2.9 4.6 4.4
Mean 13.3 11.9 11.1 8.9 6.9 5.7 8.6 10.7
±SD ±6.6 ±7.0 ±6.4 ±4.7 ±2.8 ±3.5 3.6 ±6.8
±SEM ±2.7 ±3.5 ±2.9 ±2.3 ±1.1 ±1.6 1.6 ±3.4
30
0
. 20
-c
0
C0
C-)0ii 10
0
— 0 Normal
— — A Patients
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0
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0)
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Table 4. Plasma aldosterone activity in normal subjects and patients after 3 mg of pindolol
PRA
ng/ml/hr
Ohr 0.5 hr lhr 2hr 4hr 8hr 24hr 34hr
Normal subjects
#1 21.9 11.5 9.8 6.1 12.0 7.3 14.4 —
#2 9.4 — 20.0 19.2 11.6 4.4 15.3 —
#5 6.6 8.4 10.1 12.3 4.3 4.5 5.7 5.1
#6 12.4 7.1 9.5 10.0 4.4 4.7 9.7 4.6
#7 4.6 3.4 2.6 1.7 3.3 1.9 5.1 2.9
#8 15.7 19.3 13.7 10.4 17.4 10.9 17.8 12.1
#10 6.7 7.4 6.0 8.5 7.7 6.1 5.6 4.1
Mean 11.0 9.5 10.2 9.7 8.7 5.7 10.5 5.7
±SD ±6.1 ±5.4 ±5.5 ±5.4 ±5.2 ±2.8 ±5.3 ±3.7
±SEM ±2.3 ±2.2 ±2.1 ±2.1 ±2.0 ±1.1 ±2.0 ±1.6
Patients
#3 55.6 — 116.0 112.2 28.2 74.8 49,5 —
#4 214.0 — — — 67.9 — — —
#9 94.9 49.7 35.9 54.9 41.4 70.7 103.5 105.7
#11 360.0 392.0 340.0 542.0 616.0 498.0 532.0 344.0
#12 34.8 20.9 25.1 — 73.8 51.0 28.4 31.4
#13 30.7 32.0 39.5 27.5 23.1 19.6 31.5 21.1
Mean 131.7 123.7 111.3 184.1 141.7 142.8 149.0 125.5
±sn ±130.9 ±179.3 ±132.9 ±241.2 ±233.2 ±199.7 ±216.2 ±150.4
±SEM ±53.4 ±89.6 ±59.4 ± 120.6 ±95.2 ±89.3 ±96.7 ±75.2
value (ngIlOO ml) of aldosterone of 11.0 ± (sEM)
2.31 compared with 132 ± 53.4 in the patients. All
patients had higher values than the normal volun-
teers did. In both groups, however, 3 mg of pindolol
i.v. did not influence the aldosterone levels in the
acute experiment. Renin activity (ng/mlihr) (Fig. 4)
was 3.3 ± 2.2 in the normal volunteers and 13.3 ±
6.6 (mean ± SD) in patients. Following pindolol ad-
ministration, plasma renin in normal subjects did
not show a clear trend, except for a tendency to de-
crease during the first 2 hours. The mean of the
greatest change was from 3.29 to 1.89(43%) and oc-
curred at 0.5 hours. In patients, however, plasma
renin fell distinctly until the eighth hour after pindo-
lol (from 13.3 to 5.7, 57%), without complete recov-
ery to control levels after 34 hours. There was no
relationship between the pattern of pindolol-in-
duced changes in plasma renin and basal blood
pressure or concomitant treatment with drugs such
as furosemide, methyldopa, or dihydralazine in
some patients.
Discussion
Pharmacokinetics. In our normal group, total
body clearance, volume of distribution, and half-life
of pindolol are in good agreement with reported val-
ues [1, 2, 4]. The total amount excreted unchanged
over 24 hours reaches 46% of the dose. In patients
with end-stage renal failure on chronic hemodialysis
treatment, a total body clearance of 250 to 300 mll
mm was therefore expected. This value corre-
sponds to the metabolic or nonrenal clearance in
normal man [2, 4]. Quite unexpectedly, however, in
our uremic patients, the total body clearance was
the same as it was in normal subjects. Mean values,
normalized to a body surface area of 1.73 m2, were
407 mllmin in normal subjects and 494 in patients.
This indicates that the latter were able to over-
compensate the lack of renal pindolol excretion by
increasing nonrenal elimination. It has been postu-
lated [2] that metabolism of pindolol increases grad-
ually with decreasing renal function, but creatinine
clearance and metabolic clearance rate of pindolol
are not inversely correlated [3]. In another study [4]
with two distinct groups (patients without renal im-
pairment and patients with renal impairment and a
mean creatinine clearance of 20 ml/min), the total
body clearance in uremic patients was equal to the
— o Normal ——
Patients
Time, hours
Fig. 4. Mean (± 5EM) PRA (nglml/hr) over time after 3 mg of
pindolol in normal volunteers and uremic patients.
666 Galeazzi ci a!
metabolic clearance of pindolol in nonuremics.
These data indicate that at least in moderate renal
failure, there is no increase in the rate of metabo-
lism. With propranolol it has been shown pre-
viously [12] that its kinetic behavior in patients with
extremely poor renal function differs from that in
patients with less severe renal impairment, in as
much as the former were able to metabolize pro-
pranolol faster and to a greater degree than were the
latter. The same seems to be the case with pindolol.
The patients with moderate renal impairment
(creatinine clearance, 20 ml) have the expected
clearance rate [4]; patients with no renal function
(creatinine clearance less than I ml/min, this study),
however, are able to increase the nonrenal clear-
ance rate, so that total body clearance is similar to
that found in normal subjects.
The mechanisms of increased extrarenal elimina-
tion in renal failure, which are poorly understood,
were recently discussed in detail [13]. Protein bind-
ing of pindolol is relatively low and does not differ
between normal and uremic subjects. Therefore,
changes in the free fraction of pindolol cannot ex-
plain the higher nonrenal clearance in uremic pa-
tients, nor the pharmacodynamic differences dis-
cussed later on. Accumulation of substances that
should be cleared by the kidney in progressive renal
failure, however, could induce the hepatic micro-
somal enzyme system. Although this interpretation
is speculative, it appears teleologically sound that
the liver may increase its detoxificating capacity in
severe renal failure. Whatever the exact mecha-
nisms, our data show that pharmacokinetic findings
in normal man cannot always be extrapolated to
predict kinetic behavior in disease, as is sometimes
done for dose adjustments in renal failure [14, 15].
Pharmacodynamics: (A) Cardiac effects. For
clinical purposes, pharmacokinetic knowledge is
only of primordial importance if no immediate ef-
fect of the drug can be measured, or if the substance
has a narrow therapeutic range, or both. This is not
the case for pindolol. Therefore, it seems unimpor-
tant whether or not plasma kinetics can be de-
scribed exactly, as long as the effect can be mon-
itored. In this study, the reduction in exercise-in-
duced tachycardia was used as a parameter for
cardiac effect. This may be more akin to reality than
is the isoproterenol dose-effect curve which is gen-
erally used to measure the cardiac effectiveness of
beta-blocking agents [16].
The time course of this effect did not differ
markedly between our normal and uremic subjects,
indicating that at least after one dose there is prob-
ably no build-up of an effective level of an active
metabolite in uremics. Although the variability of
this effect in both groups is impressive, the mean
effects in uremic patients were more pronounced at
all times. That it lasted longer than it did in normals
can be due to the higher dose per kilogram of body
weight that this group received. But as the apparent
volume of distribution per kilogram of body weight
is the same for both groups, equal plasma concen-
trations signify identical amounts of pindolol in the
body per kilogram of body weight. The two log
dose-response curves (effect versus log plasma con-
centration) should therefore be the same. It is evi-
dent from Fig. 3 that they are parallel, but the one
for patients is shifted to the left, indicating that the
effect is qualitatively the same, but quantitatively
more pronounced in patients with renal failure.
(B) Renal effects. Renin secretion is partly con-
troled by the adrenergic system [17]. Although this
mechanism is probably not essential for renin re-
lease [17], it plays a modulating role, especially dur-
ing stimulatory conditions such as upright posture,
physical exercise, or states of hypercatecholemia
[18-20]. The renin-inhibitory action of almost all
available beta blockers is consistent with this inter-
relationship; nevertheless, as for their variable ef-
fects on heart rate, the potential to lower plasma
renin levels may differ between individual drugs of
this class [19—22]. Thus, beta blockers with marked
agonistic activity, such as pindolol [20, 21] or bu-
furalol [22], have been found to be somewhat less
effective in decreasing PRA than are certain block-
ers without a betamimetic component [20, 21].
Apart from such general pharmacologic charac-
teristics, renin responses to beta blockade with pin-
dolol differed distinctly between our normal sub-
jects and patients with renal failure. Thus, renin in-
hibition in the latter group was more pronounced
(57 vs. 43%), reached this maximum later (8 vs. 0.5
hours), and persisted much longer (24 vs. 2 hours).
The altered pattern in the patients with uremia was
not due to concomitant drug therapy. The response
in the three patients receiving drugs with renin-
stimulating potential, such as furosemide, dihy-
dralazine [18], did not differ from that in the three
on a drug with renin-inhibitory potential, such as
methyldopa [23], or on no additional drugs; percent-
ile renin reduction (56.7 6.8% vs. 53.1 [SD]
6.1%) and the time to reach the maximal effect (4 to
8 hours) were comparable. Moreover, the diuretic
furosemide may have exerted minimal or no effect
on renin release in these patients with oliguric ter-
minal renal failure. Finally, a diuretic-dependent
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component in PRA could not be inhibited by super-
imposed beta blockade [24, 25]. Extrapolating from
a single measurement made 15 mm following admin-
istration of propranolol, Skrabal et al [26] came to a
contrary conclusion, namely that PRA may be low-
ered by beta blockade in normal subjects but not in
patients with end-stage kidney disease. The obser-
vation period used by these authors may be too
short to evaluate the beta-adrenergic stimulus for
renin release, because other investigators have
found also marked renin suppression following
treatment with beta blockade in such patients [27—
29].
The greater pulse-slowing effects and renin-inhib-
itory effects of pindolol in our patients with renal
disease as compared to the normal subjects could
not be related to variations in dose or blood levels
of the drug. This responsiveness to beta blockade
could be augmented either by an increase in the un-
derlying activity of the adrenergic nervous system
[30], or by enhanced sensitivity of beta-receptors to
the sympathetic transmitter, or by both. Previous
reports of increased plasma catecholamine concen-
trations in some patients with end-stage kidney dis-
ease [31] would be consistent with the first of these
two possibilities; no data on receptor sensitivity in
such patients are available. The latter mechanisms,
however, may be involved in patients with moder-
ate to severe essential hypertension who have also
an exaggerated response of pulse rate, or plasma re-
nm, or both to beta-blocking agents as well as vari-
ous sympatholytic agents [23, 24, 32]. Additional
factors that, theoretically, could contribute to the
prolongation of the renin-lowering effect in uremic
patients include an increase in the half-life of renin
or a prolonged presence of pindolol in kidney tis-
sue. Regarding the latter possibility, such "deep
compartments" can usually be detected kinetically;
however, this is not the case with pindolol because
of a relatively insensitive assay as compared with
the potency of the drug. Whatever the exact inter-
relations in patients with advanced renal failure, our
data suggest that altered function along the beta-ad-
renergic effector system may contribute both to the
tendency for high heart rates and plasma renin lev-
els and, conversely, to their greater responsiveness
to beta blockade.
Despite renin suppression, plasma aldosterone
concentrations remained unchanged following pin-
dolol administration in our normal subjects and in
patients with renal disease. This dissociation be-
tween the response of PRA and aldosterone levels
reveals an important role of factors other than the
renin-angiotensin system in aldosterone control fol-
lowing acute beta blockade.
This study demonstrates that pharmacokinetic
findings in normal subjects cannot in all cases be
extrapolated to predict kinetic behavior in disease
and that similar kinetics of a drug in a disease state
do not imply similar effectiveness.
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